ESMO® 2026 Highlights: Presenter Vignettes – Hong Jae Chon

Dr. Hong Jae Chon

Hong Jae Chon

MD, PhD

CHA Bundang Medical Center

1679RO

Phase 1 study of BGB-B2033 (GPC3 x 4-1BB bispecific antibody) Monotherapy: First Disclosure of Dose Optimization (DO) and Dose Escalation (DE) Update in Advanced Hepatocellular Carcinoma (HCC)